Regorafenib active in metastatic GI stromal tumors

Regorafenib active in metastatic GI stromal tumors

(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, according to a study published online May 21 in the Journal of Clinical Oncology.

Suzanne George, M.D., of the Dana-Farber Cancer Institute in Boston, and colleagues conducted a multicenter, single-stage phase II trial of oral regorafenib, 160 mg/day, in 34 patients with advanced GIST after failure of imatinib and sunitinib. The rate (CBR), defined as objective response (partial response and stable disease ≥16 weeks), was the primary study end point.

The researchers found that the CBR was 79 percent for the 33 patients who had received at least two cycles of regorafenib. Of these, 22 patients exhibited stable disease for 16 weeks or longer, and four patients achieved a partial response. Median progression-free survival (PFS) was 10 months. Hypertension and hand-foot-skin reaction were the most commonly observed grade 3 toxicities.

"In summary, regorafenib is a novel orally available multikinase inhibitor with notable activity in patients with advanced GIST after objective failure of both prior imatinib and sunitinib," the authors write. "The median PFS >10 months observed in these heavily pretreated patients supports the hypothesis that regorafenib may be a uniquely active agent in the management of GIST after treatment with imatinib and sunitinib."

Several authors disclosed financial ties to drug companies, including Bayer HealthCare Pharmaceuticals, which provided funding and the study drug.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.